# ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)

> **NCT06951646** · PHASE2 · RECRUITING · sponsor: **Second Xiangya Hospital of Central South University** · enrollment: 70 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer
- Immune Checkpoint Inhibitors (ICIs)

## Interventions

- **DRUG:** Ivonescimab
- **DRUG:** Docetaxel
- **OTHER:** Standard Treatment group

## Key facts

- **NCT ID:** NCT06951646
- **Lead sponsor:** Second Xiangya Hospital of Central South University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-10
- **Primary completion:** 2028-07-01
- **Final completion:** 2030-06-01
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2026-03-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06951646

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06951646, "ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06951646. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*